Advertisement

Human Pharmacology — Pharmacokinetics

  • Yves Cohen
Part of the Developments in Nuclear Medicine book series (DNUM, volume 4)

Abstract

Human Pharmacology and Pharmacokinetics are conducted in services of Nuclear Medicine when new radiopharmaceuticals have passed the experimental step in vitro and on animals. From the results on animals, physicians try to extrapolate to humans, healthy volunteers and patients. They compare the new radiopharmaceuticals to well-known tracers and, in some way, to other diagnostic or therapeutic methods, for instance, new brain radiopharmaceuticals, to pertechnetate, x-ray scanner and nuclear magnetic resonance imaging. The aim of the human assay is to establish the performance of the new radioactive drug, to specify the pathological indications, to delineate the limits of use, to ascertain the reproducibility of the results in different hands, to detect any side-effects and to give data for the calculation of radiation doses. The human assay needs an approval from committees for ethics and safety. Seen from the radiopharmaceuticals producer point of view, human pharmacology and pharmacokinetics of these tracers are a crucial test upon which the future of the drug will depend. Performed in hospitals, independently from the producer research department, the assays of human pharmacology and pharmacokinetics correspond to phases I and II as largely accepted nowadays. In this paper we shall discuss the organization of the assays, we shall explain the main parameters of pharmacokinetics and we shall review the literature of the most important radiopharmaceuticals. We shall also discuss the future of these assays in view of the advancement of new methods.

Keywords

Compartment Model Iminodiacetic Acid Effective Renal Plasma Flow Local Cerebral Blood Flow Methylene Diphosphonate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cohen Y, Besnard M., Radionuclides. Pharmacokinetic. In: Hundeshagen H. (ed) Handbuch der medizinischen Radiologie, Berlin-Heidelberg, Springer Verlag 1980;XV, 1:3–76.Google Scholar
  2. 2.
    Ritschel W A. Handbook of basic pharmacokinetics. 2nd edition, Drug Intelligence Publications, Hamilton, 1980.Google Scholar
  3. 3.
    Winchell H S, Baldwin R M, Lin T H. Development of 1–123 labelled amines for brain studies: localization of 1–123 iodophenylalky1 amines in rat brain. J Nucl Med 1980;21:940–46.PubMedGoogle Scholar
  4. 4.
    Winchell H S, Horst W D, Braun L, Oldendorf W H, Hattner R, Parker H. N isopropyl 1–123 p-iodoamphetamine: single pass brain uptake and washout: binding to brain synaptsomes; and localization in dog and monkey brain. J Nucl Med 1980;21: 947–52.PubMedGoogle Scholar
  5. 5.
    Carlsen L, Andresen K. 1–131 labelled N-isopropy1-p-idoamphetamine. Eur J Nucl Med 1982;7:280–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Lassen N A, Henriksen L, Holm S, Paulson 0 B, Vorstrup S, Rapin J, le Poncin-Lafitte M, Moretti J L. Xenon-133 and isopropyl-amphetamine iodine-123 studies of brain blood flow in man by single photon tomography. Proc. IIIrd World congress Nucl Med Biol Paris, Pergamon Press 1982;11:1739–43.Google Scholar
  7. 7.
    Kuhl D E, Barrio J R, Huang S C, Selin C, Ackermann R F, Lear J L, Wu JL, Lin T H, Phelps M E. Quantifying local cerebral blood flow by N-isopropy1-p-(1–123) iodoamphetamine (IMP) tomography. J Nucl Med 1982;23:196–203.PubMedGoogle Scholar
  8. 8.
    Phelps M. Positron computed tomography studies of cerebral glucose metabolism in man: theory and application in nuclear medicine. Semin Nucl Med 1981;11:32–49.PubMedCrossRefGoogle Scholar
  9. 9.
    Jones S C, Alavi A, Christman D, Montanez I, Wolf A P, Reivich M. The radiation dosimetry of 2 (F-18) fluoro 2 deoxyglucose in man. J Nucl Med 1 982;23:613–17.PubMedGoogle Scholar
  10. 10.
    Eckelman W C, Reba R C, Gibson R E, Rzeszotarski W J, Vieras F, Mazaitis JK, Francis B. Receptor binding radiotracers: a class of potential radiopharmaceuticals J Nucl Med 1979;20:350–57.Google Scholar
  11. 11.
    Gibson R E, Eckelman W C, Vieras F, Reba R C. The distribution of the muscarinic acetylcholine receptor antagonist quinuclidylbenzylate and quinnuclidylbenzylate methiodide (both tritiated) in rat, quinea pig and rabbit. J Nucl Med 1979;20:865–70.PubMedGoogle Scholar
  12. 12.
    Hanson R N, Blumberg J B, Poddubiuk Z M, Davis M A, Holman B L. Preparation and biodistribution of a 1–125 labelled betaadrenoceptor antagonist bearing a cardioselectivity enhancing N-substituent. Int JAppl Rad Isotop 1981; 32: 429–33.CrossRefGoogle Scholar
  13. 13.
    Wieland D M, Brown L E, Rogers W L, Worthington K C, Jiann-Long Wu, Clinthorne N H, Otto C A, Swanson D P, Beierwaltés W H. Myocardial imaging with a radioiodinated norepinephrine storage analogue J Nucl Med 1981;22:22–31.Google Scholar
  14. 14.
    Syrota A, Maziere M, Crouzel M, Sastre J, Prenant C. Visualization of acetylcholine receptors in the human heart using C-11 methyl QNB and positron emission tomography. Proc IIIrd World Congress Nucl Med Biol Paris, Pergamon Press 1982;111:2503–5.Google Scholar
  15. 15.
    Schelbert H R, Henze E, Phelps M E. Emission tomography of heart. Semin Nucl Med 1980;10:355–73.PubMedCrossRefGoogle Scholar
  16. 16.
    Poe N D. Rationale and radiopharmaceuticals for myocardial imaging. Semin Nucl Med 1977;7:7–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Van der Wall E E, den Hollander W, Heindendal G A K, Westera G, Majid P A, Roos J P. Dynamic myocardial scintigraphy with 1–123 labelled free fatty acids in patients with myocardial infarction. Eur J Nucl Med 1981; 6:383–389.PubMedGoogle Scholar
  18. 18.
    Hamilton G W. Myocardial imaging with thallium-201: the controversy over its clinical usefulness in ischemic heart disease. J Nucl Med 1979;20:1201–5.PubMedGoogle Scholar
  19. 19.
    Chervu L R. Radiopharmaceuticals in cardiovascular nuclear medicine. Semin Nucl Med 1979;9:241–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Pohost G M, Alpert N M, Ingwall J S, Strauss H W, Thallium redistribution: mechanism and clinical utility. Semin Nucl Med 1980;10:70–93.Google Scholar
  21. 21.
    Demangeat A, Constantinesco A, Mossard J M, Chambron J, Voegtlin R. Evaluation of myocardial perfusion and left ventricular function by Tl-201 scintigraphy after dipyridamole. Eur J Nucl Med 1981;6:491–503.PubMedCrossRefGoogle Scholar
  22. 22.
    Harris D, Taylor D, Condon B, Ackery D, Conway N. Myocardial imaging with dipyridamole: comparison of the sensitivity and specificity of Tl-201 versus M U G A. Eur J Nucl Med 1982;7:1–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Bunow B, Line B R, Horton M R, Weiss G H. Regional ventilatory clearance by xenon scintigraphy: a critical evaluation of two estimation procedures. J Nucl Med 1979;20:703–10.PubMedGoogle Scholar
  24. 24.
    Alderson P O, Line B R. Scintigraphic evaluation of regional pulmonary ventilation. Semin Nucl Med 1980;10:218–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Atkins H L, Robertson J S, Croft B V, Tsui B, Susskind H, Ellis K J, Loken M K, Treves S. MIRD dose estimate report n° 9. Estimates of radiation absorbed doses from radioxenons in lung imaging. J Nucl Med 1980;21:459–65.PubMedGoogle Scholar
  26. 26.
    Short M D, Dowsett D J, Heaf P J D, Pavia D, Thomson M L. A comparison between monodisperse Tc-99m labelled aerosol particles and Kr-81 m for assessment of lung function. J Nucl Med 1979;20:194–200.Google Scholar
  27. 27.
    Charkes N D, Makler P T, Philips C. Studies of skeletal tracer kinetics. I. Digital computer solution of a five compartment model of (F-18) fluoride kinetics in humans. J Nucl Med 1978;19:1301–9.PubMedGoogle Scholar
  28. 28.
    Charkes N D, Makler P T. Studies in skeletal tracer kinetics: V. Computer simulated Tc-99m (Sn) MDP bone scan changes in some systemic disorders: concise communication. J Nucl Med 1981;22:601–05.PubMedGoogle Scholar
  29. 29.
    Fogelman I. Skeletal uptake of diphosphonate: a review. Eur J Nucl Med 1980;5:473–6.PubMedGoogle Scholar
  30. 30.
    Fogelman I, Pearson D W, Bessent R G, Tofe A J, Francis M D. A comparison of skeletal uptakes of three diphosphonates by whole body retention: concise communication. J Nucl Med 1981;22:880–3.PubMedGoogle Scholar
  31. 31.
    Chervu L R, Blaufox M D. Renal radiopharmaceuticals. An update. Semin Nucl Med 1982;12:224–45.PubMedCrossRefGoogle Scholar
  32. 32.
    Roos J C, Koomans H A, Boer P, Oei H Y. Determination of glomerular filtration rate by In-111 DTPA. Eur J Nucl Med 1981;6:551–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Houston A S, Sampson W F D, Mac Leod M A. A compartimentai model for the distribution of In-113m DTPA and Tc-99m (Sn) DTPA in man following intravenous injection. Int J Nucl Med Biol 1979;6:85–95.PubMedCrossRefGoogle Scholar
  34. 34.
    Tauxe W N, Dubovsky E V, Mantle J A, Dustan H P, Logic J R. Measurement of effective renal plasma flow in congestive heart failure. Eur J Nucl Med 1981;6:555–59.PubMedCrossRefGoogle Scholar
  35. 35.
    Brown PH, Krishnamurthy G T, Bobba V V R, Kingston E. Radiation dose calculation for Tc-99m HIDA in health and disease. J Nucl Med 1981;22:177–83.PubMedGoogle Scholar
  36. 36.
    Bobba V R, Krishnamurthy G T, Kingston E, Brown P H, Eklem M, Turner F. The comparison of kinetics and image patterns of Tc-99m IDA derivatives in normal subjects. J Nucl Med 1981, 22:7Google Scholar
  37. 37.
    Tarolo G L, Picozzi R, Palagi B, Cammelli F. Comparative quantitative evaluation of hepatic clearance of diethyl IDA and parabutyl IDA in jaundiced and non jaundiced patients. Eur J Nucl Med 1981;6:539–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Taavitsainen M, Riihimâki E, Tâhti E. Body disappearance and liver mean transit time of Tc-99m diethyl IDA. Eur J Nucl Med 1980;5:147–50.PubMedCrossRefGoogle Scholar
  39. 39.
    Prince J R, Bancroft S, Dukstein W G. Pharmacokinetics of pertechnetate administered after pretreatment with 400mg of potassium perchlorate: concise communication. J Nucl Med 1 980; 21: 763–6PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Yves Cohen

There are no affiliations available

Personalised recommendations